Compare Quest Diagnostics Inc (DGX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Noble Corporation plc — how do they compare? Quest Diagnostics Inc trades at $237.54 (market cap $26.21B), while Noble Corporation plc trades at $44.15 (market cap $7.10B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.5%). Which is the better fit depends on your goals.
| DGX | NE | |
|---|---|---|
Market Cap | $26.21B | $7.10B |
Sector | Health | Technology |
52-Week High | $238.50 | $54.37 |
52-Week Low | $173.49 | $26.61 |
Enterprise Value | $31.97B | $8.53B |
Dividend Yield | 1.45% | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Noble Corporation (NE) trades at $44.21, up 1.52% today, with a mixed technical and fundamental backdrop. The stock exhibits a bullish trend in moving averages but faces resistance near $45-$46. Recent Q2 2026 earnings of $0.01 per share missed expectations, though the company secured $200 million in new contracts and maintains a $6.8 billion backlog. Positive cash flow from operations of $952 million in 2025 supports financial stability, but net income declined year-over-year.
The outlook is cautiously optimistic, with a consensus price target of $46 offering modest upside. Key opportunities include strong contract backlog and operational cash flow, while risks involve earnings volatility, ongoing legal investigations, and competitive pressures in offshore drilling. Analyst sentiment is divided, with 31% buy ratings reflecting balanced optimism and caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
